**Specifications Table**TableSubject area*Medicine*More specific subject area*Cardiology- cardiomyopathies*Type of data*Tables, images, questionnaire*How data was acquired*Survey (physical activity questionnaire), Echocardiography (Vivid 7 and Vivid E9 - GE Healthcare, Horten, Norway), Cardiac magnetic resonance (Magnetom Sonata and Magnetom Avanto Siemens, Erlangen, Germany), Holter*Data format*Analyzed and raw material*Experimental factors*Statistical analysis with SPSS version 21.0, SPSS Inc., Chicago, IL, USA.*Experimental features*Cross-sectional population study*Data source location*Oslo, Norway*Data accessibility*Data is with this article*

**Value of the data**•Extensive clinical information and imaging data on study subjects.•Extensive information on exercise habits and clinical endpoints in our hypertrophic cardiomyopathy study cohort.•Physical exercise questionnaire used in the survey•Complete genetic information on all mutations in our hypertrophic cardiomyopathy study cohort, with potential for pooling of data and study mutation-specific variations in phenotypic expression.

1. Data {#s0005}
=======

The data presented in this article are supplementary material to our study on vigorous exercise in hypertrophic cardiomyopathy patients. [@bib1].

[Fig. A.1](#f0005){ref-type="fig"} displays study flowchart and A.2 and A.3 represent the letter and the physical activity questionnaire sent to study participants. [Tables B.1](#t0005){ref-type="table"} and [B.2](#t0010){ref-type="table"} are logistic regression models presenting markers of hypertrophic cardiomyopathy phenotype and ventricular arrhythmias. [Table B.3](#t0015){ref-type="table"} presents specific information on genetic mutations. [Table B.4](#t0020){ref-type="table"} contains clinical and imaging data related to hypertrophic cardiomyopathy phenotype and exercise status. [Table B.5](#t0025){ref-type="table"} shows additional exercise data.

2. Experimental design, materials and methods {#s0010}
=============================================

The study design was cross-sectional. Time of study inclusion was the first clinical evaluation and echocardiogram in the outpatient clinic, Unit for Genetic Cardiac Diseases, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway ([Fig. A.1](#f0005){ref-type="fig"}). Hypertrophic cardiomyopathy genotype positive, phenotype negative (Genotype+ LVH-) and hypertrophic cardiomyopathy phenotype positive (HCM LVH+) patients were included. Inclusion commenced in 2001 and ended in 2015 [@bib1].

In May 2015 we cross checked the HCM cohort against the Norwegian death registry and found 14 deaths, of which cause of death was documented for all cases in the medical journals, and is reproduced in [Fig. A.1](#f0005){ref-type="fig"}. During May 2015 we completed a physical activity survey via letter (A.2 and A.3) among the 260 live subjects enrolled in our HCM cohort. Non-responders were contacted by phone and offered the possibility of completing the physical activity questionnaire via structured interview (A.3).

Study participants who were actively participating in organized or competitive sports at study inclusion, were defined as competitive athletes.

Funding sources {#s0015}
===============
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Appendix A {#s0020}
==========

See [Fig. A.1](#f0005){ref-type="fig"}, [Fig. A.2](#f0010){ref-type="fig"}, [Fig. A.3](#f0015){ref-type="fig"} here.Fig. A.1Study flow chart. HCM LVH+=Hypertrophic cardiomyopathy phenotype positive; Genotype+ LVH-=Hypertrophic cardiomyopathy genotype positive, phenotype negative.Fig. A.1Fig. A.2Letter sent to study participants together with physical activity questionnaire (A.3). Translated from Norwegian to English by the authors.Fig. A.2Fig. A.3Physical activity questionnaire used in our survey. Translated from Norwegian to English by the authors.Fig. A.3

Appendix B {#s0025}
==========

See [Table B.1](#t0005){ref-type="table"}, [Table B.2](#t0010){ref-type="table"}, [Table B.3](#t0015){ref-type="table"}, [Table B.4](#t0020){ref-type="table"}, [Table B.5](#t0025){ref-type="table"} here.Table B.1Markers of hypertrophic cardiomyopathy phenotype positive (HCM LVH+) (n= 121) in 187 study participants.Table B.1***Markers of HCM LVH+ (n= 121) in 187 study participants*****Univariate logistic regressionMultivariate logistic regressionOR, 95% CIPOR, 95% CIP**Athlete (yes vs. no)0.78 (0.42--1.43)0.420.73 (0.32--1.67)0.46Age (years)1.08 (1.05--1.11)\<0.0011.07 (1.05--1.11)\<0.001Body mass index (kg/m^2^)1.17 (1.07--1.28)0.0011.06 (0.97--1.17)0.20Gender (male vs. female)2.76 (1.48--5.13)0.0014.17 (1.85--9.38)0.001[^1]Table B.2Markers of ventricular arrhythmia (n=28) in 121 hypertrophic cardiomyopathy phenotype positive.Table B.2***Markers of ventricular arrhythmia (n=28) in 121 HCM LVH+*****Univariate logistic regressionMultivariate logistic regressionOR, 95% CIPOR, 95% CIP**Age (years)0.99 (0.96--1.02)0.34Athlete (yes vs. no)0.85 (0.36--2.03)0.710.72 (0.29--1.83)0.50Body mass index (kg/m²)1.02 (0.92--1.13)0.68Gender (male vs. female)1.24 (0.53--2.93)0.62  **Echocardiography**Ejection fraction (%)0.93 (0.87--0.99)0.03Global longitudinal strain (%)1.21 (1.06--1.38)0.0051.16 (0.98--1.36)0.08Left atrium diameter (mm)0.96 (0.91--1.01)0.14Left atrium area index (cm²/m²)0.91 (0.79--1.04)0.15Left ventricular maximal wall thickness (mm)1.16 (1.05--1.30)0.0061.08 (0.95--1.23)0.23LVOT peak gradient (mmHg)0.99 (0.97--1.00)0.07LVOT peak gradient ≥50 mmHg (yes vs. no)3.3 (0.93--12.00)0.07[^2]Table B.3Frequency of sarcomeric mutations (n=127) in the study cohort (n=187).Table B.3***Sarcomeric mutation****Ref.seq****Amino Acid****c.DNA****Genomic_ref. data****rs****Affected individuals***MYBPC3NM_000256.3Splice mutationc.3190+2T\>GChr11(GRCh37):g.47355106A\>Crs11335848621MYBPC3NM_000256.3p.W792Vfs\*41c.2373dupGChr11(GRCh37):g.47359281duprs39751596321MYH7NM_000257.2p.R1420Wc.4258C\>TChr14(GRCh37):g.23886807G\>Ars14521377115MYL2NM_000432.3p.R58\*c.172C\>TChr12(GRCh37):g.111352092G\>Ars7566718696MYBPC3NM_000256.3p.D770Nc.2308G\>AChr11(GRCh37):g.47360071C\>Trs362117235MYBPC3NM_000256.3p.R502Wc.1504C\>TChr11(GRCh37):g.47364249G\>Ars3758824855MYL3NM_000258.2p.A57Dc.170C\>AChr3(GRCh37):g.46902303G\>Trs1397940675MYBPC3NM_000256.3p.G1249Vc.3746G\>TChr11(GRCh37):g.47353691C\>Ars7275042593MYBPC3NM_000256.3p.E611Kc.1831G\>AChr11(GRCh37):g.47362755C\>Trs7308805553MYH7NM_000257.2p.R442Cc.1324C\>TChr14(GRCh37):g.23898247G\>Ars1488080893MYBPC3NM_000256.3p.W965\*c.965G\>AChr11(GRCh37):g.47367883C\>2MYBPC3NM_000256.3p.F271\*c.812_821+12delChr11(GRCh37):g.47369396_47369417del2MYBPC3NM_000256.3p.K185Wfs\*12c.553-562delChr11(GRCh37):g.47371417_47371426del2MYBPC3NM_000256.3p.Q969\*c.2905C\>TChr11(GRCh37):g.47356593G\>Ars3975159922MYBPC3NM_000256.3p.Y548Profs\*19c.1641_1642delChr11(GRCh37):g.47363690_47363691delrs3981232792MYBPC3NM_000256.3p.I49delc.146_148delChr11(GRCh37):g.47372934_47372936delrs7812076612MYH7NM_000257.2p.T1377Mc.4130C\>TChr14(GRCh37):g.23887458G\>Ars3975162012MYH7NM_000257.2p.V606Mc.1816G\>AChr14(GRCh37):g.23896866C\>Trs1219136272MYH7NM_000257.2p.D554Ec.1662C\>AChr14(GRCh37):g.23897020G\>Trs7508284772TINNI3NM_000363.4p.D196Nc.586G\>AChr19(GRCh37):g.55663249C\>Trs1048947272MYBPC3NM_000256.3p.Y237Sc.710A\>CChr11(GRCh37):g.47370037T\>Grs3975160701MYBPC3NM_000256.3p.L1238Pc.3713T\>CChr11(GRCh37):g.47353724A\>Grs7308807021MYBPC3NM_000256.3p.Q998Ec.2992C\>GChr11(GRCh37):g.47355475G\>Crs115701121MYBPC3NM_000256.3p.P955Rfs\*95)c.2864_2865delChr11(GRCh37):g.47356633_47356634delrs3975159901MYBPC3NM_000256.3p.Y816\*c.2448C\>AChr11(GRCh37):g.47359096G\>1MYBPC3NM_000256.3p.Y79\*c.237C\>GChr11(GRCh37):g.47372845G\>Crs7308806981MYH7NM_000257.2p.S1924Afs\*9c.5769delGChr14(GRCh37):g.23882989del1MYH7NM_000257.2p.R1818Wc.5452C\>TChr14(GRCh37):g.23884311G\>Ars7630730721MYH7NM_000257.2p.R1696Qc.5090G\>AChr14(GRCh37):g.23884905C\>Trs7668319161MYH7NM_000257.2p.R1677Hc.5030G\>AChr14(GRCh37):g.23884965C\>Trs7308809141MYH7NM_000257.2p.M982Tc.2945T\>CChr14(GRCh37):g.23892910A\>Grs1455326151MYH7NM_000257.2p.I913_Q914delinsKc.2738delChr14(GRCh37):g.23893298_23893300del1MYH7NM_000257.2p.R858Cc.2572C\>TChr14(GRCh37):g.23894085G\>Ars27541581MYH7NM_000257.2p.M849Wc.2546T\>CChr14(GRCh37):g.23894111A\>Grs3975161561MYH7NM_000257.2p.A797Tc.2389G\>AChr14(GRCh37):g.23894525C\>Trs32187161TINNI3NM_000363.4p.V147Lc.439G\>CChr19(GRCh37):g.55665508C\>Grs7777825511TNNI3NM_000363.4p.A157Vc.470C\>TChr19(GRCh37):g.55665477G\>Ars3975163531TNNT2NM_001001430.2p.R278Hc.833G\>AChr1(GRCh37):g.201328372C\>Trs3975164841TNNT2NM_001001430.2p.K253Rc.758A\>GChr1(GRCh37):g.201330429T\>Crs37302381TNNT2NM_001001430.2p.E195Kc.583G\>AChr1(GRCh37):g.201331147C\>Trs1500082051Table B.4Clinical and cardiac imaging characteristics of 187 study participants, grouped according to phenotype and exercise status (competitive athletes vs. subjects not fulfilling competitive athlete definition).Table B.4***Genotype+LVH−(n= 66)****HCM LVH+(n=121)*****Not fulfilling definition of competitive athlete (n=50)Competitive athlete (n=16)Not fulfilling definition of competitive athlete (n=110)Competitive athlete (n=11)**Age, years41 ± 1527 ± 1055 ± 1448 ± 15Atrial fibrillation, n (%)0019 (17)0Betablocker therapy, n (%)8 (16)089 (81)7 (64)Body mass index, kg/m²24 ± 4.423 ± 2.827 ± 425 ± 4Female, n (%)33 (66)9 (56)45 (41)2 (18)Hypertension, n (%)3 (6)012 (11)0Implantable cardiac defibrillator, n (%)0015 (14)1 (9)Primary prevention, n (%)12 (80)1 (100)Secondary prevention, n (%)3 (20)0          Lifetime vigorous exercise, hours1396 (0- 10208)5706 (2689- 10384)1464 (0- 35776)7940 (2527- 13993)Sarcomere protein mutation, n (%)50 (100)16 (100)53 (48)8 (73)Ventricular arrhythmias, n (%)0025 (23)3 (27)Cardiac arrest, n (%)3 (3)0NSVT, n (%)22 (20)3 (27)          Vigorous exercise age 7- 20 years, hours999 (0- 8752)3400 (65- 8663)549 (0- 10067)1986 (728- 8489)Vigorously exercising at study inclusion, n (%)20 (40)16 (100)23 (21)11 (100)          **Echocardiography**E/A1.5 ± 0.61.9 ± 0.51.3 ± 0.71.5 ± 0.6e\', cm/s10.8 ± 0.314.4 ± 0.25.9 ± 38.5 ± 3E/e\'7.0 ± 2.65.4 ± 0.915 ± 910 ± 6Ejection fraction, %61 ± 658 ± 462 ± 760 ± 5Global longitudinal strain, %-21.5 ± 2.2-21.2 ± 2.3-16.5 ± 3.5-17.6 ± 3.2Interventricular septal diameter, mm8.5 ± 28.4 ± 116.9 ± 0.414.4 ± 0.4Left atrium diameter, mm34 ± 634 ± 343 ± 840 ± 8Left atrium area index, cm²/m²8.7 ± 39.5 ± 212.5 ± 312.0 ± 3LV end-diastolic diameter, mm48 ± 451 ± 347 ± 651 ± 6LV end-diastolic diameter index, mm/m²27 ± 327 ± 224 ± 426 ± 3LV end-diastolic volume, cm³85 ± 26118 ± 2981 ± 29103 ± 40LV end-diastolic volume index, cm³/m²47 ± 1260 ± 1341 ± 1352 ± 16LV end-systolic diameter, mm31 ± 434 ± 428 ± 632 ± 5LV end-systolic diameter index, mm/m²17 ± 218 ± 215 ± 316 ± 1LV end-systolic volume, cm³34 ± 1150 ± 1631 ± 1440 ± 14LV end-systolic volume index, cm³/m²19 ± 525 ± 716 ± 622 ± 7LV mass, g131 ± 34142 ± 30255 ± 91262 ± 106LV mass index, g/m²72 ± 1673 ± 13132 ± 46130 ± 41LV posterior wall diameter, mm7.7 ± 17.6 ± 110.2 ± 210.4 ± 2LVOT max gradient, rest/Valsalva, mmHg14 (2- 128)4 (2- 47)LVOT max gradient, stress-echo, mmHg §56 (4- 166)41 (16- 65)LVOT max gradient ≥ 50 mmHg, n (%)0044 (40)1 (9)Maximal wall thickness, mm8.68.619.116.4Mitral regurgitation, n (%)14 (28)1 (6)76 (69)3 (27)Mild regurgitation, n (%)14 (100)1 (100)46 (61)3 (100)Moderate regurgitation, n (%)0026 (34)0Severe regurgitation, n (%)004 (5)0          Stroke volume, cm³52 ± 1768 ±1750 ± 1764 ± 27Stroke volume index, cm³/m²29 ± 835 ± 825 ± 831 ± 12**Cardiac magnetic resonance, n (%)n=0n=0n=69 (63)n=7 (64)**Ejection fraction, %70 ± 961 ± 6LGE, n (%) \#41 (60)4 (57)LGE, % of LV mass \#0 (0- 23)0 (0-17)LV mass, g231 ± 93198 ± 72LV mass index, g/m²119 ± 4697 ± 29Maximal wall thickness, mm22.6 ± 617.8 ± 3[^3][^4][^5]Table B.5Frequency of types of main sport conducted in 187 study participants.Table B.5***Type of sport****Frequency****Percent***No exercise history4624.6Cycling2714.4Running2513.4Soccer158.0Calisthenics137.0Cross country skiing105.3Handball94.8Swimming94.8Aerobics52.7Dancing52.7Field hockey42.1Basketball42.1Athletics21.1Gymnastics21.1Karate21.1Pingpong21.1Archery10.5Badminton10.5Figure skating10.5Speed skating10.5Alpine skiing10.5Indoor cycling10.5Tennis10.5Total187100

Transparency document. Supplementary material {#s0035}
=============================================

Supplementary material.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2017.08.018](http://dx.doi.org/10.1016/j.dib.2017.08.018){#ir0005}.

[^1]: Values are odds ratio (OR) and p-values by univariate and multivariate logistic regression. CI=confidence interval; HCM LVH+=hypertrophic cardiomyopathy phenotype positive.

[^2]: Values are odds ratio (OR) and p-values by univariate and multivariate logistic regression. CI=confidence interval; HCM LVH+=hypertrophic cardiomyopathy phenotype positive; LVOT=left ventricular outlet tract.

[^3]: Values are mean ± SD or n (%) or median (range). Genotype+ LVH-=hypertrophic cardiomyopathy genotype positive, phenotype negative; HCM LVH+=hypertrophic cardiomyopathy phenotype positive; LGE=late gadolinium enhancement; LV=left ventricle; LVOT=left ventricular outlet tract; NSVT=non-sustained ventricular tachycardia.

[^4]: § n=36.

[^5]: \# n=74.
